Is serputinib/serpatinib (Ruitu) a targeted anti-cancer drug?

Selpercatinib is a targeted anti-cancer drug that belongs to the receptor tyrosine kinase inhibitors (TKI). It is a targeted drug targeting RET (rearranged transforming growth factor receptor) gene mutations and is mainly used to treat cancers with RET gene mutations, including non-small cell lung cancer (NSCLC), thyroid cancer and other cancer types. RET gene mutations usually lead to abnormal proliferation of cancer cells. Septinib reduces the proliferation and metastasis of cancer cells by specifically inhibiting the activity of RET kinase.

Seputinib’s targeting mechanism makes it more precise and effective than traditional chemotherapy drugs in treating certain types of cancer. It can selectively inhibit tumor cells with RET gene mutations while having less impact on healthy cells, thereby reducing common side effects of traditional chemotherapy, such as immune suppression, hair loss, etc. Seputinib has also been shown to be effective against cancers harboring RET gene fusions, making it a promising treatment, especially for patients with advanced and metastatic cancers.

It is worth noting that seputinib is approved by the FDA for the treatment of RET gene mutation-positive non-small cell lung cancer (NSCLC) and RET fusion-positive medullary thyroid cancer (MTC). Therefore, seputinib is not only a targeted therapy drug, but also because of its specificity in targeting RET gene mutations, it is one of the representatives of precision medicine and can provide personalized treatment for patients with specific gene mutations.

In summary, although seputinib is effective in treating RET gene mutation-positive cancers, its drug resistance remains a challenge in clinical treatment. With continued research, these problems may be addressed through combination therapy or new drug development in the future, further enhancing the clinical application prospects of seputinib.

Reference:https://en.wikipedia.org/wiki/Selpercatinib